Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 369

1.

Rates of ERBB2 Alterations Across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-amplified Acral Melanoma.

Gottesdiener LS, O'Connor S, Busam KJ, Won H, Solit DB, Hyman DM, Shoushtari AN.

Clin Cancer Res. 2018 Aug 9. pii: clincanres.1397.2018. doi: 10.1158/1078-0432.CCR-18-1397. [Epub ahead of print]

PMID:
30093446
2.

Reflectance Confocal Microscopic and En Face Histopathologic Correlation of the Dermoscopic "Circle Within a Circle" in Lentigo Maligna.

Navarrete-Dechent C, Liopyris K, Cordova M, Busam KJ, Marghoob AA, Chen CJ.

JAMA Dermatol. 2018 Jul 25. doi: 10.1001/jamadermatol.2018.2216. [Epub ahead of print] No abstract available.

PMID:
30046812
3.

PRAME Expression in Melanocytic Tumors.

Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ.

Am J Surg Pathol. 2018 Jul 24. doi: 10.1097/PAS.0000000000001134. [Epub ahead of print]

PMID:
30045064
4.

Kaposi's Sarcoma After Autologous Stem-Cell Transplantation and Rituximab Treatment.

Geller S, Dickson MA, Busam KJ, Myskowski PL.

J Oncol Pract. 2018 Jul 25:JOP1800246. doi: 10.1200/JOP.18.00246. [Epub ahead of print] No abstract available.

PMID:
30044684
5.

Solitary fibrous tumor presenting on the scalp: a potential diagnostic pitfall.

Mori S, Lezcano C, Miraflor AP, Busam KJ, Lee EH.

J Cutan Pathol. 2018 Aug;45(8):557-560. doi: 10.1111/cup.13272. No abstract available.

PMID:
30004148
6.

Comparison of melanoma gene expression score with histopathology, fluorescence in situ hybridization, and SNP array for the classification of melanocytic neoplasms.

Reimann JDR, Salim S, Velazquez EF, Wang L, Williams KM, Flejter WL, Brooke L, Sunder S, Busam KJ.

Mod Pathol. 2018 Jun 28. doi: 10.1038/s41379-018-0087-6. [Epub ahead of print]

PMID:
29955141
7.

Comment on: Screening for malignant melanoma-a critical assessment in historical perspective.

Marghoob AA, Marchetti M, Halpern AC, Busam KJ.

Dermatol Pract Concept. 2018 Apr 30;8(2):73-74. doi: 10.5826/dpc.0802a01. eCollection 2018 Apr. No abstract available.

8.

Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.

Thomas NE, Edmiston SN, Orlow I, Kanetsky PA, Luo L, Gibbs DC, Parrish EA, Hao H, Busam KJ, Armstrong BK, Kricker A, Cust AE, Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Dwyer T, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group.

J Invest Dermatol. 2018 May 9. pii: S0022-202X(18)31962-6. doi: 10.1016/j.jid.2018.04.025. [Epub ahead of print]

9.

Primary and Metastatic Melanoma With NTRK Fusions.

Lezcano C, Shoushtari AN, Ariyan C, Hollmann TJ, Busam KJ.

Am J Surg Pathol. 2018 Aug;42(8):1052-1058. doi: 10.1097/PAS.0000000000001070.

PMID:
29683819
10.

Immunohistochemical Detection of γ/δ T Lymphocytes in Formalin-fixed Paraffin-embedded Tissues.

Jungbluth AA, Frosina D, Fayad M, Pulitzer MP, Dogan A, Busam KJ, Imai N, Gnjatic S.

Appl Immunohistochem Mol Morphol. 2018 Mar 6. doi: 10.1097/PAI.0000000000000650. [Epub ahead of print]

PMID:
29517505
11.

Ponatinib-induced ichthyosiform drug eruption: insights into acquired ichthyosis.

Xu H, Busam KJ, Mauro MJ, Markova A.

Dermatol Online J. 2017 Oct 15;23(10). pii: 13030/qt2zf9r6vw.

PMID:
29469781
12.

BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi.

Francis JH, Grossniklaus HE, Habib LA, Marr B, Abramson DH, Busam KJ.

Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):117-121. doi: 10.1167/iovs.17-22517.

PMID:
29332123
13.

Quantitative assessment of neuropilin-2 as a simple and sensitive diagnostic assay for spitzoid melanocytic lesions.

Eisenstein A, Panova IP, Chung HJ, Goldberg LJ, Zhang Q, Lazova R, Bhawan J, Busam KJ, Symanowski JT, Alani RM, Ryu B.

Melanoma Res. 2018 Feb;28(1):71-75. doi: 10.1097/CMR.0000000000000416.

14.

Facial swelling and foreign body granulomatous reaction to hyaluronic acid filler in the setting of tyrosine kinase inhibitor therapy.

Hibler BP, Yan BY, Marchetti MA, Momtahen S, Busam KJ, Rossi AM.

J Eur Acad Dermatol Venereol. 2018 Jun;32(6):e225-e227. doi: 10.1111/jdv.14749. Epub 2018 Jan 3. No abstract available.

PMID:
29224214
15.

The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort.

Ozkaya N, Rosenblum MK, Durham BH, Pichardo JD, Abdel-Wahab O, Hameed MR, Busam KJ, Travis WD, Diamond EL, Dogan A.

Mod Pathol. 2018 Apr;31(4):581-597. doi: 10.1038/modpathol.2017.160. Epub 2017 Dec 1.

PMID:
29192649
16.

Gene expression signature as an ancillary method in the diagnosis of desmoplastic melanoma.

Clarke LE, Pimentel JD, Zalaznick H, Wang L, Busam KJ.

Hum Pathol. 2017 Dec;70:113-120. doi: 10.1016/j.humpath.2017.10.005. Epub 2017 Oct 24.

17.

Atypical Melanocytic Proliferations: A Review of the Literature.

Ensslin CJ, Hibler BP, Lee EH, Nehal KS, Busam KJ, Rossi AM.

Dermatol Surg. 2018 Feb;44(2):159-174. doi: 10.1097/DSS.0000000000001367. Review.

PMID:
29059147
18.

The interaction between vitamin D receptor polymorphisms and sun exposure around time of diagnosis influences melanoma survival.

Orlow I, Shi Y, Kanetsky PA, Thomas NE, Luo L, Corrales-Guerrero S, Cust AE, Sacchetto L, Zanetti R, Rosso S, Armstrong BK, Dwyer T, Venn A, Gallagher RP, Gruber SB, Marrett LD, Anton-Culver H, Busam K, Begg CB, Berwick M; GEM Study Group.

Pigment Cell Melanoma Res. 2018 Mar;31(2):287-296. doi: 10.1111/pcmr.12653. Epub 2017 Nov 5.

PMID:
28990310
19.

Recurrent nevus as a pitfall of melanoma diagnosis under reflectance confocal microscopy.

Yélamos O, Jain M, Busam KJ, Marghoob AA.

Australas J Dermatol. 2017 Oct 8. doi: 10.1111/ajd.12733. [Epub ahead of print] No abstract available.

PMID:
28990158
20.

Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma.

Thomas NE, Edmiston SN, Kanetsky PA, Busam KJ, Kricker A, Armstrong BK, Cust AE, Anton-Culver H, Gruber SB, Luo L, Orlow I, Reiner AS, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Dwyer T, Parrish EA, Hao H, Gibbs DC, Frank JS, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group.

J Invest Dermatol. 2017 Dec;137(12):2588-2598. doi: 10.1016/j.jid.2017.07.832. Epub 2017 Aug 24.

PMID:
28842324
21.

Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic Melanoma.

Vernali S, Waxweiler WT, Dillon PM, Kanetsky PA, Orlow I, Luo L, Busam KJ, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Dwyer T, Cust AE, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group.

JAMA Dermatol. 2017 Oct 1;153(10):1026-1031. doi: 10.1001/jamadermatol.2017.2444.

PMID:
28746718
22.

Reference values for skin microanatomy: A systematic review and meta-analysis of ex vivo studies.

Xu H, Fonseca M, Wolner Z, Chung E, Wu X, Geller S, Dusza SW, DeRosa AP, Marghoob AA, Busam KJ, Halpern AC, Marchetti MA.

J Am Acad Dermatol. 2017 Dec;77(6):1133-1144.e4. doi: 10.1016/j.jaad.2017.06.009. Epub 2017 Jul 14. Review.

PMID:
28716435
23.

Functional melanoma-risk variant IRF4 rs12203592 associated with Breslow thickness: a pooled international study of primary melanomas.

Gibbs DC, Ward SV, Orlow I, Cadby G, Kanetsky PA, Luo L, Busam KJ, Kricker A, Armstrong BK, Cust AE, Anton-Culver H, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group.

Br J Dermatol. 2017 Nov;177(5):e180-e182. doi: 10.1111/bjd.15784. Epub 2017 Oct 6. No abstract available.

PMID:
28667740
24.

Primary cutaneous marginal zone lymphoma with leptomeningeal involvement and a durable response to rituximab.

Virmani P, Busam K, Myskowski PL, Yang A, Magro C, Horwitz S.

JAAD Case Rep. 2017 Jun 14;3(4):269-272. doi: 10.1016/j.jdcr.2017.02.024. eCollection 2017 Jul. No abstract available.

25.

[Expression of cancer testis (CT) antigens in pediatric and adolescent melanomas].

Behrendt N, Schultewolter T, Busam K, Frosina D, Spagnoli G, Jungbluth A.

Pathologe. 2017 Jul;38(4):303-311. doi: 10.1007/s00292-017-0311-z. Review. German.

PMID:
28631119
26.

Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy.

Ferris LK, Jansen B, Ho J, Busam KJ, Gross K, Hansen DD, Alsobrook JP 2nd, Yao Z, Peck GL, Gerami P.

JAMA Dermatol. 2017 Jul 1;153(7):675-680. doi: 10.1001/jamadermatol.2017.0473.

27.

Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms.

Wang L, Busam KJ, Benayed R, Cimera R, Wang J, Denley R, Rao M, Aryeequaye R, Mullaney K, Cao L, Ladanyi M, Hameed M.

J Mol Diagn. 2017 May;19(3):387-396. doi: 10.1016/j.jmoldx.2016.11.005.

28.

Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma.

Liang WS, Hendricks W, Kiefer J, Schmidt J, Sekar S, Carpten J, Craig DW, Adkins J, Cuyugan L, Manojlovic Z, Halperin RF, Helland A, Nasser S, Legendre C, Hurley LH, Sivaprakasam K, Johnson DB, Crandall H, Busam KJ, Zismann V, Deluca V, Lee J, Sekulic A, Ariyan CE, Sosman J, Trent J.

Genome Res. 2017 Apr;27(4):524-532. doi: 10.1101/gr.213348.116.

29.

Solitary Large Keratoacanthomas of the Head and Neck: An Observational Study.

Rossi AM, Park B, Qi B, Lee EH, Busam KJ, Nehal KS.

Dermatol Surg. 2017 Jun;43(6):810-816. doi: 10.1097/DSS.0000000000001080.

PMID:
28296794
30.

Frequency of Subungual Melanoma in Longitudinal Melanonychia: A Single-Center Experience.

Decker A, Connolly KL, Lee EH, Busam KJ, Nehal KS.

Dermatol Surg. 2017 Jun;43(6):798-804. doi: 10.1097/DSS.0000000000001112.

PMID:
28296790
31.

Locally Recurrent Lentigo Maligna and Lentigo Maligna Melanoma: Characteristics and Time to Recurrence After Surgery.

Connolly KL, Hibler BP, Lee EH, Rossi AM, Busam KJ, Nehal KS.

Dermatol Surg. 2017 Jun;43(6):792-797. doi: 10.1097/DSS.0000000000001118.

PMID:
28296789
32.

Reduced H3K27me3 expression in Merkel cell polyoma virus-positive tumors.

Busam KJ, Pulitzer MP, Coit DC, Arcila M, Leng D, Jungbluth AA, Wiesner T.

Mod Pathol. 2017 Jun;30(6):877-883. doi: 10.1038/modpathol.2017.8. Epub 2017 Mar 10.

33.

A Woman With Recurrent Facial Ulcers.

Hibler BP, Busam KJ, Pulitzer MP, Rossi AM.

Am J Dermatopathol. 2017 Feb;39(2):155-156. doi: 10.1097/DAD.0000000000000480. No abstract available.

PMID:
28134735
34.

Hedgehog Signaling Inhibitors Fail to Reduce Merkel Cell Carcinoma Viability.

Carroll TM, Williams JS, Daily K, Rogers T, Gelb T, Coxon A, Wang SQ, Crago AM, Busam KJ, Brownell I.

J Invest Dermatol. 2017 May;137(5):1187-1190. doi: 10.1016/j.jid.2017.01.008. Epub 2017 Jan 25. No abstract available.

35.

The NF1 gene in tumor syndromes and melanoma.

Kiuru M, Busam KJ.

Lab Invest. 2017 Feb;97(2):146-157. doi: 10.1038/labinvest.2016.142. Epub 2017 Jan 9. Review.

36.

Optimizing Outcomes for Cutaneous Head and Neck Melanoma.

Connolly KL, Busam KJ, Nehal KS.

JAMA Dermatol. 2017 Mar 1;153(3):267-268. doi: 10.1001/jamadermatol.2016.4604. No abstract available.

PMID:
28002549
37.

Dermatofibrosarcoma Protuberans-Like Tumor With COL1A1 Copy Number Gain in the Absence of t(17;22).

Saab J, Rosenthal IM, Wang L, Busam KJ, Nehal KS, Dickson MA, Hameed MR, Hollmann TJ.

Am J Dermatopathol. 2017 Apr;39(4):304-309. doi: 10.1097/DAD.0000000000000746.

38.

Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors.

Zarbo A, Belum VR, Sibaud V, Oudard S, Postow MA, Hsieh JJ, Motzer RJ, Busam KJ, Lacouture ME.

Br J Dermatol. 2017 Jun;176(6):1649-1652. doi: 10.1111/bjd.15237. Epub 2017 Apr 24.

39.

Reduced H3K27me3 Expression Is Common in Nodular Melanomas of Childhood Associated With Congenital Melanocytic Nevi But Not in Proliferative Nodules.

Busam KJ, Shah KN, Gerami P, Sitzman T, Jungbluth AA, Kinsler V.

Am J Surg Pathol. 2017 Mar;41(3):396-404. doi: 10.1097/PAS.0000000000000769.

40.

An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi.

Clarke LE, Flake DD 2nd, Busam K, Cockerell C, Helm K, McNiff J, Reed J, Tschen J, Kim J, Barnhill R, Elenitsas R, Prieto VG, Nelson J, Kimbrell H, Kolquist KA, Brown KL, Warf MB, Roa BB, Wenstrup RJ.

Cancer. 2017 Feb 15;123(4):617-628. doi: 10.1002/cncr.30385. Epub 2016 Oct 21.

41.

Variants in autophagy-related genes and clinical characteristics in melanoma: a population-based study.

White KA, Luo L, Thompson TA, Torres S, Hu CA, Thomas NE, Lilyquist J, Anton-Culver H, Gruber SB, From L, Busam KJ, Orlow I, Kanetsky PA, Marrett LD, Gallagher RP, Sacchetto L, Rosso S, Dwyer T, Cust AE, Begg CB, Berwick M; GEM Study Group.

Cancer Med. 2016 Nov;5(11):3336-3345. doi: 10.1002/cam4.929. Epub 2016 Oct 17.

42.

Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma.

Gerami P, Yao Z, Polsky D, Jansen B, Busam K, Ho J, Martini M, Ferris LK.

J Am Acad Dermatol. 2017 Jan;76(1):114-120.e2. doi: 10.1016/j.jaad.2016.07.038. Epub 2016 Oct 1.

43.

Prepubertal Melanoma Arising within a Medium-Sized Congenital Melanocytic Nevus.

Lalor L, Busam K, Shah K.

Pediatr Dermatol. 2016 Nov;33(6):e372-e374. doi: 10.1111/pde.12961. Epub 2016 Aug 30.

44.

Discordance Between Cobas BRAF V600 Testing and VE1 Immunohistochemistry in a Melanoma Patient With Bone Marrow Metastases.

Rapisuwon S, Busam KJ, Parks K, Chapman PB, Lee E, Atkins MB.

Am J Dermatopathol. 2016 Sep;38(9):687-9. doi: 10.1097/DAD.0000000000000660.

45.

Primary Cutaneous Ewing Sarcoma With Ewsr1-Erg Fusion.

Molina-Ruiz AM, Busam KJ.

J Cutan Pathol. 2016 Sep;43(9):729-34. doi: 10.1111/cup.12747. No abstract available.

PMID:
27526022
46.

Time to local recurrence of lentigo maligna: Implications for future studies.

Connolly KL, Nijhawan RI, Dusza SW, Busam KJ, Nehal KS.

J Am Acad Dermatol. 2016 Jun;74(6):1247-8. doi: 10.1016/j.jaad.2016.02.1150. No abstract available.

47.

Biologically distinct subsets of nevi.

Rogers T, Marino ML, Raciti P, Jain M, Busam KJ, Marchetti MA, Marghoob AA.

G Ital Dermatol Venereol. 2016 Aug;151(4):365-84. Epub 2016 Apr 27. Review.

48.

Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanoma.

Taylor NJ, Thomas NE, Anton-Culver H, Armstrong BK, Begg CB, Busam KJ, Cust AE, Dwyer T, From L, Gallagher RP, Gruber SB, Nishri DE, Orlow I, Rosso S, Venn AJ, Zanetti R, Berwick M, Kanetsky PA; GEM Study Group.

Int J Cancer. 2016 Sep 15;139(6):1217-22. doi: 10.1002/ijc.30157. Epub 2016 May 30.

49.

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.

Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, Motzer RJ, Wu S, Busam KJ, Wolchok JD, Lacouture ME.

Eur J Cancer. 2016 Jun;60:12-25. doi: 10.1016/j.ejca.2016.02.010. Epub 2016 Apr 1. Review.

50.

Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.

Wiesner T, Kutzner H, Cerroni L, Mihm MC Jr, Busam KJ, Murali R.

Pathology. 2016 Feb;48(2):113-31. doi: 10.1016/j.pathol.2015.12.007. Epub 2016 Jan 18. Review.

Supplemental Content

Support Center